Allergy Therapeutics to present key scientific findings from across its research portfolio at EAACI

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, has announced that the Group will be sharing key scientific findings from across its research portfolio at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place from 10-12 July 2021.

The EAACI Congress is the world’s largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 12,000 clinicians, researchers, and allied health professionals, dedicated to improving the health of people affected by allergic diseases.

Among its 17 posters being presented, Allergy Therapeutics will share findings from:

·      a preclinical study evaluating the plant-based cucumber mosaic virus-like-particle (CuMV) used in the Group’s peanut allergy vaccine candidate, which is due to enter the clinic in 2022. This virus-like-particle (VLP) technology, genetically fused with peanut allergen, is a new strategy for peanut allergy vaccination.  

·   a retrospective cohort study, intending to reflect real world conditions, which used prescription data from patients in Germany to assess the impact of subcutaneous immunotherapy to treat grass or tree pollen allergies.

·    three approaches examining the tolerability of, and impact on allergy symptoms from, ImmunoBON, the Group’s novel, protein-based oral product for the general treatment of allergies, which is based on the lower incidence of allergies shown by people who live near or on a livestock farm, the so-called “farm effect”.

Allergy Therapeutics will also be hosting two symposia; The Group’s Digital Company Symposium is being held on Saturday 10 July at 18:00-19:30 (CET) and will consist of three presentations covering Allergy Therapeutics’ latest publication on the MATA meta-analysis, lead by Prof. Ralph Mӧsges; the current landscape of insect venom allergy presented by Prof. Thilo Jakob, and the scientific background of our newest product, ImmunoBON, presented by Prof. Erika Jensen-Jarolim. A Live Q&A will follow the symposium where the audience will be able to ask questions to the speakers.

Following Erika’s presentation on ImmunoBON on Saturday evening, Franziska Roth-Walter will explain the role of iron deficiency and betalactoglobulin in atopy and how supplementing patients with these micronutrients can help to improve their quality of life in a mini hybrid symposium on Sunday 11 July at 09:00-09:30 (CET).

Manuel Llobet, CEO at Allergy Therapeutics, commented: “At Allergy Therapeutics, our mission is to transform lives by breaking new ground in immunology treatments. Our research programmes are going beyond symptom management, to focus on directly treating the cause of allergy. The research that we’re delighted to be sharing with research colleagues at this year’s EAACI congress demonstrates the strength of our science and our commitment to developing novel, short-course immunotherapies that can help patients to change the way they think about their allergies and better manage their conditions.”

The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation is below.

Abstract NamePresentationPoster number
MAJOR ALLERGEN QUANTIFICATION IN A HOUSE DUST MITE ADJUVANTED THERAPEUTIC PRODUCT: ANALYTICAL DEVELOPMENTSSviatlana Starchenka158
IDENTIFICATION AND QUANTIFICATION OF MAJOR HOUSE DUST MITE ALLERGEN – Der p 23 – IN DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR ALLERGEN IMMUNOTHERAPYPetra Visic157
IMPACT OF THE ALLERGIC DISEASE ON THE CLASSROOM PERFORMANCE AND DAILY ACTIVITIES OF CHILDREN AND ADOLESCENTS WITH ALLERGIC ASTHMA CAUSED BY HOUSE DUST MITES.Catalina Gómez177
IMPACT OF ALLERGIC DISEASE ON THE WORK PERFORMANCE AND DAILY ACTIVITIES OF PARENTS/CAREGIVERS OF CHILDREN AND ADOLESCENTS WITH ALLERGIC ASTHMA CAUSED BY HOUSE DUST MITECatalina Gómez180
EFFECTS OF A HOUSE MITE ALLERGOID ABSORBED INTO MUCROCRYSTALLINE TYROSINE ON THE IMPACT OF ASTHMA DUE TO MITE ALLERGY ON SCHOOL PERFORMANCE AND DAILY ACTIVITIES OF CHILDREN AND ADOLESCENTCatalina Gómez182
EFFECTIVENESS AND SAFETY OF A SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY WITH A MICROCRYSTALLINE TYROSINE-ADSORBED NATIVE EXTRACT IN PATIENTS SENSITISED TO QUERCUS SPPImmaculada Pérez-Rangel183
STRONG REDUCTION IN NASAL PROVOCATION TEST OUTCOME AFTER TREATMENT WITH A MODIFIED BIRCH SCIT PRODUCT COMPARED TO PLACEBO: A RETROSPECTIVE SUB-STUDY OF A PIVOTAL PHASE III STUDY WITH PQ BIRCHPieter-Jan de Kam234
SAFETY AND IMMUNOLOGY RESULTS FROM A PIVOTAL PHASE III STUDY WITH A MODIFIED BIRCH SCIT PRODUCTPieter-Jan de Kam214
BASELINE SCORE DURING CONJUNCTIVAL PROVOCATION TESTING IS AN IMPORTANT PREDICTOR OF TREATMENT EFFECT – POST-HOC ANALYSES OF A PHASE II STUDY WITH A MODIFIED GRASS SCIT PRODUCT.Pieter-Jan de Kam192
SHORT-COURSE SPECIFIC IMMUNOTHERAPY (SIT) WITH MODIFIED GRASS/TREE ALLERGOID USING A MICROCRYSTALLINE TYROSINE (MCT) & MONOPHOSPHORYL LIPID A (MPL) ADJUVANT SYSTEM DECREASES BIRCH Ig E LEVELSDietrich Stollewerk213
A THREE-SIDED APPROACH TO EVALUATE BOVINE BETA-LACTOGLOBULIN IN A LOZENGE – TARGETED MICRONUTRITION IN PATIENTS WITH ALLERGIC RHINOCONJUNCTIVITISKarl-Christian Bergmann195
TAPAS – A LONG-TERM NON-INTERVENTIONAL STUDY USING MCT (MICROCRYSTALLINE TYROSINE) ADSORBED ALLERGOIDS TO DEMONSTRATE NON-INFERIORITY OF CHILDREN COMPARED TO ADULTSRalph Mӧsges197
DESIGN, SAFETY AND EFFICACY PROFILE OF THE CUCUMBER MOSAIC VIRUS-LIKE PARTICLE (CuMV) MODIFIED BY GENETIC FUSION WITH Fel d1 FOR CAT ALLERGY TREATMENTThalia L. Carreño159
DESIGN, SAFETY AND EFFICACY PROFILE OF THE CUCUMBER MOSAIC VIRUS-LIKE PARTICLE (CuMV) MODIFIED BY GENETIC FUSION WITH Ara h2 FOR PEANUT ALLERGY TREATMENTThalia L. Carreño160
THE HEALTH AND ECONOMIC IMPACT OF ALLERGEN THERAPY IN PATIENTS WITH ALLERGICRHINOCONJUNCTIVITIS: REAL-WORD EVIDENCE FROM THE CZECH REPUBLICTomáš Doležal981
EFFECTIVENESS AND SAFETY OF A MICROCRYSTALLINE TYROSINE-ADSORBED CUPRESSUS ARIZONICA ALLERGOID IN PATIENTS WITH ALLERGIC RHINITIS WITH AND WITHOUT ASTHMA: RESULTS FROM A RESTROSPECTIVE STUDYRosa María Blanco1011
TARGET – IMPACT OF AUTHORIZED MICROCRYSTALLINE TYROSINE (MCT) – ADSORBED POLLEN SCIT ALLERGOIDS ON ALLERGIC RHINITIS (AR) UNDER REAL LIFE CONDITIONSChristian Vogelberg994
Pioneering a new age – fighting allergic disease on all fronts! Saturday 10 July 2021 18:00 – 19:30 (CET)
IntroductionChair: Dr. Ignacio Dávila3D Adjuvants Mode of Action VideoSymposium Overview& Introductions5 mins
SpeakerProf. Ralph MösgesMCT- an evidence-based adjuvant in allergen immunotherapy25 mins
Speaker:Prof. Thilo JakobInsect Venom Allergy – exploring the current landscape25 mins
Speaker:Prof. Erika Jensen-JarolimBeta-lactoglobulin – from farm stable dust to a lozenge inducingimmune resilience in allergic diseases25 mins
Chair: Dr. IgnacioDávilaQ&A10 mins
Allergy Therapeutics Mini Symposium Sunday 11 July 2021 09:00 – 09:30 (CET)
FranziskaRoth-WalterAmeliorating atopy by targeted micronutrient supplementation withbeta-lactoglobulin30 mins

Abstracts and links to the posters are expected to be made available on the Company’s website from 12 July 2021.

No new material price sensitive information is expected to be disclosed on Allergy Therapeutics at the EAACI Congress. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be mild, like

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive Officer, Manuel

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards Agency (FSA),

Restaurant fined after peanut allergy teen suffered shock

A restaurant operator who served a curry containing nuts to a woman with an allergy has been fined. Eleanor Lincoln suffered anaphylactic shock after eating the takeaway for her 18th birthday in March 2021. She was treated in

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy restrictions too

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million at an

Online group supports parents coping with child allergies

A mother has set up a support group for parents coping with child allergies, offering them a “safe place to share”. Mother-of-two Claire Stone, from Thorndon, Suffolk, started Pippa Friendly to help other families in the same boat

Beware of ‘thunder fever

Doctors today warned asthmatics and hay fever sufferers face a higher risk of deadly allergic reactions due to the current thunderstorms. The combination of high pollen counts and wet weather creates a phenomenon known as ‘thunder fever’ or ‘thunderstorm

Allergies in children have risen seven-fold in past 15 years

Allergies in children have soared seven-fold in the last 15 years, new research shows. Now four in every ten children are allergic to something and scientists are still trying to understand what is causing the dramatic rise. Britain has

No more posts to show